Skip to main content
Top
Published in: Immunologic Research 6/2021

Open Access 01-12-2021 | Rheumatoid Arthritis | Original Article

Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association

Authors: Khalaf Kridin, Eran Shavit, Giovanni Damiani, Arnon D Cohen

Published in: Immunologic Research | Issue 6/2021

Login to get access

Abstract

Despite some common pathogenic themes, the association of hidradenitis suppurativa (HS) and rheumatoid arthritis (RA) has been poorly investigated. We aimed to evaluate the bidirectional association between HS and RA. A population-based study was conducted to compare HS patients (n = 6779) with age-, sex- and ethnicity-matched control subjects (n = 33,260) with regard to the incidence of new-onset and the prevalence of preexisting RA. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were estimated. The prevalence of preexisting RA was greater among patients with HS relative to controls (0.5% vs 0.3%. respectively; p = 0.019). The odds of being diagnosed with HS were 1.6-fold higher in patients with a history of RA (fully-adjusted OR, 1.66; 95% CI, 1.11–2.49; p = 0.014). The incidence rate of new-onset RA was estimated at 4.3 (95% CI, 2.5–6.8) and 2.4 (95% CI, 1.8–3.2) cases per 10,000 person-years among patients with HS and controls, respectively. The risk of RA was comparable between patients with HS and controls (fully-adjusted HR, 1.45; 95% CI, 0.77–2.72; p = 0.249). Compared to other patients with HS, those with HS and comorbid RA were older, had a higher prevalence of diabetes mellitus, hypertension, and hyperlipidemia, and had a comparable risk of all-cause mortality. In conclusions, a preexisting diagnosis of RA predisposes individuals to develop HS. Clinicians managing patients with HS and RA should be aware of this association. Further research is required to delineate the underlying pathomechanism of this observation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. JAMA - J Am Med Assoc. 2017. p. 2019–32. Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. JAMA - J Am Med Assoc. 2017. p. 2019–32.
2.
go back to reference Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol Mosby Inc.; 2020. 82: 1045–58. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol Mosby Inc.; 2020. 82: 1045–58.
3.
go back to reference Jemec GBE, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J. Am. Acad. Dermatol. [Internet]. Mosby Inc.; 2015;73:S4–7. Jemec GBE, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J. Am. Acad. Dermatol. [Internet]. Mosby Inc.; 2015;73:S4–7.
4.
go back to reference Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J. Am. Acad. Dermatol. [Internet]. J Am Acad Dermatol; 2008 [cited 2021 May 23];59:596–601. Available from: https://pubmed.ncbi.nlm.nih.gov/18674845/. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J. Am. Acad. Dermatol. [Internet]. J Am Acad Dermatol; 2008 [cited 2021 May 23];59:596–601. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​18674845/​.
5.
go back to reference Nguyen T V., Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life [Internet]. J. Eur. Acad. Dermatology Venereol. Blackwell Publishing Ltd; 2021 [cited 2021 May 23]. p. 50–61. Available from: https://pubmed.ncbi.nlm.nih.gov/32460374/. Nguyen T V., Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life [Internet]. J. Eur. Acad. Dermatology Venereol. Blackwell Publishing Ltd; 2021 [cited 2021 May 23]. p. 50–61. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​32460374/​.
6.
go back to reference Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis [Internet]. Lancet. Lancet Publishing Group; 2016. p. 2023–38. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis [Internet]. Lancet. Lancet Publishing Group; 2016. p. 2023–38.
7.
go back to reference Alam MS, LaBelle B. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. JAAD Case Reports [Internet]. 2020;6:219–21.CrossRef Alam MS, LaBelle B. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. JAAD Case Reports [Internet]. 2020;6:219–21.CrossRef
9.
go back to reference Kridin K, Jones VA, Patel PM, Gibson FT, Amber KT, Cohen AD. Hidradenitis suppurativa and pemphigus: a cross-sectional study. Arch Dermatol Res. 2020;312:501–5.CrossRef Kridin K, Jones VA, Patel PM, Gibson FT, Amber KT, Cohen AD. Hidradenitis suppurativa and pemphigus: a cross-sectional study. Arch Dermatol Res. 2020;312:501–5.CrossRef
10.
go back to reference Kridin K, Amber KT, Comaneshter D, Cohen AD. Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. Clin Exp Dermatol. 2020;45:565–71.CrossRef Kridin K, Amber KT, Comaneshter D, Cohen AD. Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. Clin Exp Dermatol. 2020;45:565–71.CrossRef
11.
go back to reference Kridin K, Jones VA, Patel PM, Zelber-Sagi S, Hammers CM, Damiani G, et al. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunol Res. 2020;68:373–8.CrossRef Kridin K, Jones VA, Patel PM, Zelber-Sagi S, Hammers CM, Damiani G, et al. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunol Res. 2020;68:373–8.CrossRef
12.
go back to reference Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study. Clin Rheumatol. 2021;40:521–8.CrossRef Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study. Clin Rheumatol. 2021;40:521–8.CrossRef
13.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef
14.
go back to reference Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital di Dermatologia e Venereol. 2018;153:243–55. Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital di Dermatologia e Venereol. 2018;153:243–55.
15.
go back to reference Sayah A, English JC. Rheumatoid arthritis: A review of the cutaneous manifestations. J. Am. Acad. Dermatol. 2005. p. 191–209. Sayah A, English JC. Rheumatoid arthritis: A review of the cutaneous manifestations. J. Am. Acad. Dermatol. 2005. p. 191–209.
16.
go back to reference Rosner IA, Burg CG, Wisnieski JJ, Schacter BZ, Richter DE. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J Rheumatol. 1993;20:684–7.PubMed Rosner IA, Burg CG, Wisnieski JJ, Schacter BZ, Richter DE. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J Rheumatol. 1993;20:684–7.PubMed
17.
go back to reference Shlyankevich J, Chen AJ, Kim GE, Kimball AB (2014) Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol Mosby Inc 71:1144–50. Shlyankevich J, Chen AJ, Kim GE, Kimball AB (2014) Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol Mosby Inc 71:1144–50.
18.
go back to reference Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, et al. Hidradenitis suppurativa associated with spondyloarthritis - Results from a multicenter national prospective study. J Rheumatol. 2014;41:490–4.CrossRef Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, et al. Hidradenitis suppurativa associated with spondyloarthritis - Results from a multicenter national prospective study. J Rheumatol. 2014;41:490–4.CrossRef
19.
go back to reference Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatology Venereol. 2018;32:1784–90.CrossRef Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatology Venereol. 2018;32:1784–90.CrossRef
20.
go back to reference Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa. JAMA Dermatol. 2020;156:342–5.CrossRef Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa. JAMA Dermatol. 2020;156:342–5.CrossRef
21.
go back to reference Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol. Clin. 2016. p. 7–16. Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol. Clin. 2016. p. 7–16.
22.
go back to reference Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422–34.CrossRef Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422–34.CrossRef
23.
go back to reference Scott DL, Ibrahim F, Farewell V, Go’Keeffe A, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ [Internet]. BMJ Publishing Group; 2015;350. Scott DL, Ibrahim F, Farewell V, Go’Keeffe A, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ [Internet]. BMJ Publishing Group; 2015;350.
24.
go back to reference Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;29:86–92. Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;29:86–92.
25.
go back to reference Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2018;179:413–9. Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2018;179:413–9.
26.
go back to reference Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. [Internet]. J Exp Med; 2010;207:1135–43. Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. [Internet]. J Exp Med; 2010;207:1135–43.
27.
go back to reference Ingram JR. The epidemiology of hidradenitis suppurativa*. Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;183:990–8. Ingram JR. The epidemiology of hidradenitis suppurativa*. Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;183:990–8.
Metadata
Title
Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association
Authors
Khalaf Kridin
Eran Shavit
Giovanni Damiani
Arnon D Cohen
Publication date
01-12-2021
Publisher
Springer US
Published in
Immunologic Research / Issue 6/2021
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-021-09221-4

Other articles of this Issue 6/2021

Immunologic Research 6/2021 Go to the issue